Accepted Manuscript Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials Anju Suhag, MD, Gabriele Saccone, MD, Vincenzo Berghella, MD PII:

S0002-9378(15)00261-6

DOI:

10.1016/j.ajog.2015.03.031

Reference:

YMOB 10319

To appear in:

American Journal of Obstetrics and Gynecology

Received Date: 20 December 2014 Revised Date:

5 March 2015

Accepted Date: 17 March 2015

Please cite this article as: Suhag A, Saccone G, Berghella V, Vaginal progesterone for maintenance tocolysis: a systematic review and meta-analysis of randomized trials, American Journal of Obstetrics and Gynecology (2015), doi: 10.1016/j.ajog.2015.03.031. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

1

Vaginal progesterone for maintenance tocolysis: a systematic review and meta-analysis of

2

randomized trials

3

Anju Suhag MD,1 Gabriele Saccone MD,2 Vincenzo Berghella MD1

4

1

5

Jefferson University Hospital, Philadelphia, PA, USA

6

2

7

University of Naples Federico II, Naples, Italy

8

Correspondence: Vincenzo Berghella, MD, Department of Obstetrics and Gynecology, Division

9

of Maternal-Fetal Medicine, Thomas Jefferson University, 833 Chestnut Street, First Floor,

RI PT

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Thomas

M AN U

SC

Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine,

Philadelphia, PA 19107, USA.

11

E-mail: [email protected]

12

Disclosure: The authors report no conflict of interest

13

Financial Support: No financial support was received for this study

14

Level of evidence: IA

15

Word count: Abstract 274; Text 1705; Tables 2; Figures 4

16

Obstetrics

19 20

EP

18

AC C

17

TE D

10

21 22 23 1

ACCEPTED MANUSCRIPT

Condensation

25

Maintenance tocolysis with vaginal progesterone prevents preterm birth

26

Short titles

27

Vaginal progesterone for maintenance tocolysis

28

SC

29

RI PT

24

30

M AN U

31 32 33 34

38 39 40 41

EP

37

AC C

36

TE D

35

42 43 44

2

ACCEPTED MANUSCRIPT

Abstract

46

Objective: To evaluate the efficacy of maintenance tocolysis with vaginal progesterone

47

compared to placebo in singleton gestations with arrested preterm labor (PTL) in a meta-analysis

48

of randomized controlled trials (RCTs).

49

Data Source: Searches were performed in MEDLINE, OVID, Scopus, ClinicalTrials.gov and

50

the Cochrane Central Register of Controlled Trials with the use of a combination of keywords

51

and text words related to “progesterone,” “tocolysis” and “preterm labor” from 1966 until

52

November 2014.

53

Study eligibility criteria: We included all randomized trials of singleton gestations that had

54

arrested preterm labor and then were randomized to maintenance tocolysis treatment with either

55

vaginal progesterone or control (either placebo or no treatment). All published randomized

56

studies on progesterone tocolysis were carefully reviewed. Exclusion criteria included

57

maintenance tocolysis in women with preterm premature rupture of membrane, maintenance

58

tocolysis with 17-alpha-hydroxyprogesterone caproate and maintenance tocolysis with oral

59

progesterone.

60

Study appraisal and synthesis methods: The summary measures were reported as risk ratios

61

(RR), with 95% confidence interval (95% CI). The primary outcome was preterm birth less than

62

37 weeks.

63

Results: Five randomized trials, including 441 singleton gestations, were analyzed. Women who

64

received vaginal progesterone maintenance tocolysis for arrested preterm labor had a

65

significantly lower rate of preterm birth less than 37 weeks (42% vs 58%; RR 0.71, 95% CI 0.57,

66

0.90; three trials, 298 women). Women who received vaginal progesterone had significantly

67

longer latency (mean difference 13.80 days, 95% CI 3.97, 23.63; four trials, 368 women), later

68

gestational age at delivery (mean difference 1.29 weeks, 95% CI 0.43, 2.15; four trials, 368

69

women), lower rate of recurrent PTL (24% vs 46%; RR 0.51, 95% CI 0.31, 0.84; two trials, 122

70

women) and lower rate of neonatal sepsis (2% vs 7%; RR 0.34, 95% CI 0.12, 0.98; four trials,

71

368 women).

AC C

EP

TE D

M AN U

SC

RI PT

45

3

ACCEPTED MANUSCRIPT

Conclusions: Maintenance tocolysis with vaginal progesterone is associated with prevention of

73

preterm birth, significant prolongation of pregnancy, and lower neonatal sepsis. However, given

74

the frequent lack of blinding and the generally poor quality of the trials, we do not currently

75

suggest a change in clinical care of women with arrested PTL. We suggest instead well-designed

76

placebo-controlled randomized trials to confirm the findings of our meta-analysis.

77

Key words: preterm labor; preterm birth; tocolysis; progesterone

SC

78 79

M AN U

80 81 82 83

88 89 90 91

EP

87

AC C

86

TE D

84 85

RI PT

72

92 93

4

ACCEPTED MANUSCRIPT

Introduction

95

Preterm birth (PTB), defined as birth between 20 and 36 6/7 weeks, is responsible for the

96

majority of the neonatal morbidity and mortality in the United States,1,2,3 and 35% of all U.S.

97

healthcare spending on infants.4 Globally, about 28% of the 4 million annual neonatal deaths are

98

directly attributable to PTB.5

99

Preterm labor (PTL) is the final pathway for about 50% of all PTB. Tocolytic agents are drugs

RI PT

94

that can slow or stop labor contractions in the attempt to delay births preceded by PTL. Primary

101

tocolysis is defined as tocolysis given on initial presentation of women with PTL. In most of

102

these women, PTL stops, but as their risk of PTB remains high, some have advocated use of

103

maintenance tocolysis, i.e. tocolysis after arrested PTL. So far, no maintenance tocolytic agent

104

has been shown to be beneficial in preventing PTB.1 Recently, progesterone has been used

105

successfully for prevention of PTB, in particular in asymptomatic singleton gestations with either

106

short CL6,7 or with prior spontaneous PTB.8 The efficacy of vaginal progesterone in preventing

107

PTB in women with arrested PTL is not clear.

108

Objective

109

The aim of this study was to evaluate the efficacy of maintenance tocolysis with vaginal

110

progesterone compared to placebo in singleton gestations with arrested PTL in a meta-analysis of

111

randomized trials.

TE D

EP

112

M AN U

SC

100

Methods

114

Study design

115

The research protocol was designed a priori, defining methods for searching the literature,

116

including and examining articles, and extracting and analyzing data. Searches were performed in

117

MEDLINE, OVID, Scopus, ClinicalTrials.gov and the Cochrane Central Register of Controlled

118

Trials with the use of a combination of keywords and text words: “progesterone,” “tocolysis”

119

and “preterm labor” from 1966 until November 2014. To locate additional publications, we

120

reviewed proceedings of international society meetings on PTB and tocolysis and bibliographies

AC C

113

5

ACCEPTED MANUSCRIPT

of identified studies and reviews articles. No restrictions for language or geographic location

122

were applied.

123

We included randomized trials of singleton gestations that had arrested PTL and then were

124

randomized to maintenance tocolysis treatment with either vaginal progesterone or control

125

(either placebo or no treatment). All published randomized studies on progesterone tocolysis

126

were carefully reviewed. Exclusion criteria included quasi-randomized trials (i.e. trials in which

127

allocation was done on the basis of a pseudo-random sequence, e.g. odd/even hospital number or

128

date of birth, alternation), maintenance tocolysis in women with preterm premature rupture of

129

membrane (PPROM), maintenance tocolysis with 17-alpha-hydroxyprogesterone caproate (17P)

130

and maintenance tocolysis with oral progesterone.

131

Before data extraction, the protocol was registered with PROSPERO (Registration number:

132

CRD42014013706).9 The meta-analysis was reported following the Preferred Reporting Item for

133

Systematic Reviews and Meta-analyses (PRISMA) statement.10,11

134

Data abstraction was completed by three independent investigators (GS, AS, VB). Each

135

investigator independently abstracted data from each study and analyzed data separately.

136

Differences were reviewed, and further resolved by common review of the entire data. All

137

authors were contacted for missing data.

138

The risk of bias in each included study was assessed by using the criteria outlined in the

139

Cochrane Handbook for Systematic Reviews of Interventions.10 Seven domains related to risk of

140

bias were assessed in each included trial since there is evidence that these issues are associated

141

with biased estimates of treatment effect: 1) random sequence generation; 2) allocation

142

concealment; 3) blinding of participants and personnel; 4) blinding of outcome assessment; 5)

143

incomplete outcome data; 6) selective reporting; and 7) other bias. Review authors’ judgments

144

were categorized as “low risk”, “high risk” or “unclear risk” of bias.10 Risk of bias was assessed

145

by two investigators (AS, GS). Disagreements were resolved by consensus with a third reviewer

146

(VB).

147

The primary outcome was PTB

Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.

We sought to evaluate the efficacy of maintenance tocolysis with vaginal progesterone compared to control (placebo or no treatment) in singleton gesta...
2MB Sizes 6 Downloads 25 Views